EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

4’-Fluorouridine mitigates lethal infection with pandemic human and highly pathogenic avian influenza viruses

Carolin M Lieber, Megha Aggarwal, Jeong-Joong Yoon, Robert M Cox, Hae-Ji Kang, Julien Sourimant, Mart Toots, Scott K Johnson, Cheryl A Jones, Zachary M Sticher, Alexander A Kolykhalov, Manohar T Saindane und 6 weitere

PLOS Pathogens · 2023

DOI: 10.1371/journal.ppat.1011342 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Pathogens, 2023. Verfasst von Carolin M Lieber und 17 weiteren Autor:innen. Beteiligte Einrichtung: Center for Translational Antiviral Research, Georgia State University Institute for Biomedical Sciences, Atlanta, Georgia, United States of America. Hauptthemen laut MEDLINE: Influenza, Human, Influenza A Virus, H5N1 Subtype, Influenza A Virus, H1N1 Subtype, COVID-19. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Influenza outbreaks are associated with substantial morbidity, mortality and economic burden. Next generation antivirals are needed to treat seasonal infections and prepare against zoonotic spillover of avian influenza viruses with pandemic potential. Having previously identified oral efficacy of the nucleoside analog 4’-Fluorouridine (4’-FlU, EIDD-2749) against SARS-CoV-2 and respiratory syncytial virus (RSV), we explored activity of the compound against seasonal and highly pathogenic influenza (HPAI) viruses in cell culture, human airway epithelium (HAE) models, and/or two animal models, ferrets and mice, that assess IAV transmission and lethal viral pneumonia, respectively. 4’-FlU inhibited a panel of relevant influenza A and B viruses with nanomolar to sub-micromolar potency in HAE cells. In vitro polymerase assays revealed immediate chain termination of IAV polymerase after 4’-FlU incorporation, in contrast to delayed chain termination of SARS-CoV-2 and RSV polymerase. Once-daily oral treatment of ferrets with 2 mg/kg 4’-FlU initiated 12 hours after infection rapidly stopped virus shedding and prevented transmission to untreated sentinels. Treatment of mice infected with a lethal inoculum of pandemic A/CA/07/2009 (H1N1)pdm09 (pdmCa09) with 4’-FlU alleviated pneumonia. Three doses mediated complete survival when treatment was initiated up to 60 hours after infection, indicating a broad time window for effective intervention. Therapeutic oral 4’-FlU ensured survival of animals infected with HPAI A/VN/12/2003 (H5N1) and of immunocompromised mice infected with pdmCa09. Recoverees were protected against homologous reinfection. This study defines the mechanistic foundation for high sensitivity of influenza viruses to 4’-FlU and supports 4’-FlU as developmental candidate for the treatment of seasonal and pandemic influenza.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza, HumanInfluenza A Virus, H5N1 SubtypeInfluenza A Virus, H1N1 SubtypeCOVID-19Influenza A virusRespiratory Syncytial Virus, HumanOrthomyxoviridae InfectionsHumansAnimalsMiceFerretsSARS-CoV-2Uracil Nucleotides

Substanzen

4'-fluorouridineUracil Nucleotides

Autor:innen und Institutionen

  • Center for Translational Antiviral Research, Georgia State University Institute for Biomedical Sciences, Atlanta, Georgia, United States of America.
  • Center for Vaccines and Immunology, University of Georgia, Athens, Georgia, United States of America.
  • Emory Institute for Drug Development, Emory University, Atlanta, Georgia, United States of America.
  • Department of Immunology, Interfaculty Institute for Cell Biology, Eberhard Karls University Tübingen, Tübingen, Germany.
  • Department of Pathology, College of Veterinary Medicine, University of Georgia, Athens, Georgia, United States of America.

ORCID-Profile: Richard K Plemper

Förderung

  • NIAID NIH HHS
  • Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases

Zitieren

APA

Lieber, C. M., Aggarwal, M., Yoon, J. J., Cox, R. M., Kang, H. J., Sourimant, J., Toots, M., Johnson, S. K., Jones, C. A., Sticher, Z. M., Kolykhalov, A. A., Saindane, M. T., Tompkins, S. M., Planz, O., Painter, G. R., Natchus, M. G., Sakamoto, K., & Plemper, R. K. (2023). 4’-Fluorouridine mitigates lethal infection with pandemic human and highly pathogenic avian influenza viruses. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1011342

Vancouver

Lieber CM, Aggarwal M, Yoon JJ, Cox RM, Kang HJ, Sourimant J, et al. 4’-Fluorouridine mitigates lethal infection with pandemic human and highly pathogenic avian influenza viruses. PLOS Pathogens. 2023. doi:10.1371/journal.ppat.1011342

BibTeX
@article{Lieber2023,
  author = {Lieber, Carolin M and Aggarwal, Megha and Yoon, Jeong-Joong and Cox, Robert M and Kang, Hae-Ji and Sourimant, Julien and Toots, Mart and Johnson, Scott K and Jones, Cheryl A and Sticher, Zachary M and Kolykhalov, Alexander A and Saindane, Manohar T and Tompkins, Stephen M and Planz, Oliver and Painter, George R and Natchus, Michael G and Sakamoto, Kaori and Plemper, Richard K},
  title = {4’-Fluorouridine mitigates lethal infection with pandemic human and highly pathogenic avian influenza viruses},
  journal = {PLOS Pathogens},
  year = {2023},
  doi = {10.1371/journal.ppat.1011342}
}
Kostenlos starten →